Details

Autor(en) / Beteiligte

• Patel, Roshal R.
• He, Kewen
• Barsoumian, Hampartsoum B.
• Chang, Joe Y.
• Tang, Chad
• Verma, Vivek
• Comeaux, Nathan
• Chun, Stephen G.
• Gandhi, Saumil
• Truong, Mylene T.
• Erasmus, Jeremy J.
• Hong, David S.
• Lee, Percy P.
• Ning, Matthew S.
• Nguyen, Quynh-Nhu
• Heymach, John V.
• Altan, Mehmet
• Blumenschein, George
• Fossella, Frank V.
• Sezen, Duygu
• Chen, Dawei
• Carter, Brett W.
• Davies, Michael A.
• Glitza, Isabella C.
• Diab, Adi
• Ferrarotto, Renata
• Cabanillas, Maria E.
• Yuan, Ying
• Shah, Shalin J.
• Parra, Edwin R.
• Sun, Baohua
• Cortez, Maria Angelica
• Welsh, James W.

Titel

High-dose irradiation in combination with non-ablative low-dose radiation to treat metastatic disease after progression on immunotherapy: Results of a phase II trial

Ist Teil von

• Radiotherapy and oncology, 2021-09, Vol.162, p.60-67

Ort / Verlag

Elsevier B.V

Erscheinungsjahr

2021

Quelle

Alma/SFX Local Collection

Beschreibungen/Notizen

• •HD-RT ± LD-RT to separate lesions can be safely delivered for IO refractory patients.•HD-RT + LD-RT safely improved lesion-specific response for IO refractory patients.•LD-RT may be a consideration for large tumors or multiple isocenters.•T- and NK cell infiltration was enhanced in lesions treated with LD-RT. To report early findings from a phase II trial of high-dose radiotherapy (HD-RT) with or without low-dose RT (LD-RT) for metastatic cancer. Eligible patients had metastatic disease that progressed on immunotherapy within 6 months. Patients were given either HD-RT (20–70 Gy total; 3–12.5 Gy/f), or HD-RT + LD-RT (0.5–2 Gy/f up to 1–10 Gy total) to separate lesions, with continued immunotherapy. Radiographic response was assessed per RECIST 1.1 and Immune-Related Response Criteria (irRC). Primary endpoints: (1) 4-month disease control (DCR, complete/partial response [CR/PR] or stable disease [SD]) or an overall response (ORR, CR/PR) at any point in ≥10% of patients, per RECIST 1.1; (2) dose-limiting toxicity within 3 months not exceeding 30%. Secondary endpoint was lesion-specific response. Seventy-four patients (NSCLC, n = 38; melanoma n = 21) were analyzed (39 HD-RT and 35 HD-RT + LD-RT). The median follow-up time was 13.6 months. The primary endpoint was met for 72 evaluable patients, with a 4-month DCR of 42% (47% [16/34] vs. 37% [14/38] in HD-RT + LD-RT vs. HD-RT, P = 0.38), and 19% ORR at any time (26% [9/34] vs. 13% [5/38] in HD-RT + LD-RT vs. HD-RT, P = 0.27). Three patients had toxicity ≥grade 3. LD-RT lesion response (53%) was improved compared to nonirradiated lesions in HD-RT + LD-RT (23%, P = 0.002) and HD-RT (11%, P < 0.001). T- and NK cell infiltration was enhanced in lesions treated with LD-RT. HD-RT plus LD-RT safely improved lesion-specific response in patients with immune resistant solid tumors by promoting infiltration of effector immune cells into the tumor microenvironment.